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Members of the B7/CD28 family of immune checkpoints,
such as CTLA4, PD1 and PDL-1, play critical roles in
T cell regulation and have emerged as promising drug
targets for cancer immunotherapy. We hypothesize that
additional novel members of the B7/CD28 family play a
role as negative immune regulators and thus may serve as
targets for therapeutic mAbs. Utilising Compugen’s pre-
dictive discovery platform, we identified nine novel mem-
bers of this family that may serve as immune checkpoints.
The therapeutic relevance of three of these proteins,
CGEN-15001T, CGEN-15022, and CGEN-15049, was
confirmed following the validation of their immunomodu-
latory properties and their expression in various cancers.
Two of these proteins, CGEN-15001T and CGEN-15022,
are the basis of a license and collaboration agreement
recently signed with Bayer as targets for cancer immu-
notherapy. Here we present results obtained for an addi-
tional novel immune checkpoint, CGEN-15049. Following
its ectopic expression on cancer cell lines, CGEN-15049
inhibits the activity of NK cells and cytotoxic T cells
(CTLs). The fusion protein, consisting of the extracellular
domain of CGEN-15049 fused to an IgG Fc domain, dis-
plays robust inhibition of T cell activation and enhances
iTregs differentiation. IHC studies indicate that CGEN-
15049 is expressed in tumour cells of numerous types of
cancers, as well as in tumour infiltrating immune cells.
Based on its immunomodulatory activities on several types
of immune cells which play key roles in cancer immune
evasion, together with its expression pattern,CGEN-15049
may serve as mAb target for cancer immunotherapy.
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